Regulation of pro-inflammatory signalling networks by ubiquitin: Identification of novel targets for anti-inflammatory drugs

Expert Reviews in Molecular Medicine

Volumn 7, Issue 12, 2005, Pages

  Evans, Paul C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Deubiquitinating enzyme; E3 ligase; Inflammation; NF kappa B; Proteasome; Ubiquitin

Indexed keywords

ANTIINFLAMMATORY AGENT; CARRIER PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; PROTEASOME;

AMINO ACID SEQUENCE; ANTIINFLAMMATORY ACTIVITY; DRUG TARGETING; ENZYME MECHANISM; ENZYME SPECIFICITY; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; BIOLOGICAL MODEL; HUMAN; METABOLISM;

MAMMALIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; MODELS, BIOLOGICAL; NF-KAPPA B; OXIDATIVE STRESS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

EID: 31044443091     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399405009415     Document Type: Review

References (101)

1. Giles, J. (2004) Chemistry Nobel for trio who revealed molecular death-tag. Nature 431, 729,
2. Goldstein, G. et al. (1975) Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci U S A 72, 11-15,
3. Pickart, C.M. and Eddins, M.J. (2004) Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 1695, 55-72,
4. Glickman, M.H. and Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82, 373-428,
5. Abriel, H. et al. (1999) Defective regulation of the epithelial Na+ channel by Nedd4 in Liddle's syndrome. J Clin Invest 103, 667-673,
6. Staub, O. et al. (1996) WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome. Embo J 15, 2371-2380,
7. Izzi, L. and Attisano, L. (2004) Regulation of the TGFbeta signalling pathway by ubiquitin-mediated degradation. Oncogene 23, 2071-2078,
8. Yang, Y., Li, C.C. and Weissman, A.M. (2004) Regulating the p53 system through ubiquitination. Oncogene 23, 2096-2106,
9. Ghosh, S., May, M.J. and Kopp, E.B. (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16, 225-260,
10. Wing, S.S. (2003) Deubiquitinating enzymes - the importance of driving in reverse along the ubiquitin-proteasome pathway. Int J Biochem Cell Biol 35, 590-605,
11. Amerik, A.Y. and Hochstrasser, M. (2004) Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta 1695, 189-207,
12. Borodovsky, A. et al. (2001) A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. Embo J 20, 5187-5196,
13. Verma, R. et al. (2002) Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 298, 611-615,
14. Chen, X., Zhang, B. and Fischer, J.A. (2002) A specific protein substrate for a deubiquitinating enzyme: Liquid facets is the substrate of Fat facets. Genes Dev 16, 289-294,
15. Trompouki, E. et al. (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424, 793-796,
16. Brummelkamp, T.R. et al. (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 424, 797-801,
17. Kovalenko, A. et al. (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424, 801-805,
18. Cummins, J.M. and Vogelstein, B. (2004) HAUSP is required for p53 destabilization. Cell Cycle 3, 689-692,
19. Cummins, J.M. et al. (2004) Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 428, 1 p following 486,
20. Wilson, S.M. et al. (2002) Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat Genet 32, 420-425,
21. Saigoh, K. et al. (1999) Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 23, 47-51,
22. Jensen, D.E. et al. (1998) BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16, 1097-1112,
23. Jensen, D.E. and Rauscher, F.J., 3rd (1999) Defining biochemical functions for the BRCA1 tumor suppressor protein: analysis of the BRCA1 binding protein BAP1. Cancer Lett 143 Suppl 1, S13-17,
24. Mallery, D.L., Vandenberg, C.J. and Hiom, K. (2002) Activation of the E3 ligase function of the BRCA1 /BARD1 complex by polyubiquitin chains. Embo J 21, 6755-6762,
25. Ben-Neriah, Y. (2002) Regulatory functions of ubiquitination in the immune system. Nat Immunol 3, 20-26,
26. Zhu, Y. et al. (1996) DUB-1, a deubiquitinating enzyme with growth-suppressing activity. Proc Natl Acad Sci U S A 93, 3275-3279,
27. Zhu, Y. et al. (1997) DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes. J Biol Chem 272, 51-57,
28. Baek, K.H. et al. (2004) DUB-1A, a novel deubiquitinating enzyme subfamily member, is polyubiquitinated and cytokine-inducible in B-lymphocytes. J Biol Chem 279, 2368-2376,
29. Baek, K.H. et al. (2001) DUB-2A, a new member of the DUB subfamily of hematopoietic deubiquitinating enzymes. Blood 98, 636-642,
30. Pickart, C.M. (2001) Ubiquitin enters the new millennium. Mol Cell 8, 499-504,
31. Tenno, T. et al. (2004) Structural basis for distinct roles of Lys63- and Lys48-linked polyubiquitin chains. Genes Cells 9, 865-875,
32. Varadan, R. et al. (2004) Solution conformation of Lys63-linked di-ubiquitin chain provides clues to functional diversity of polyubiquitin signaling. J Biol Chem 279, 7055-7063,
33. Holler, D. and Dikic, I. (2004) Receptor endocytosis via ubiquitin-dependent and -independent pathways. Biochem Pharmacol 67, 1013-1017,
34. Hicke, L. (2001) Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2, 195-201,
35. Fang, D. and Liu, Y.C. (2001) Proteolysis-independent regulation of P13K by Cbl-b-mediated ubiquitination in T cells. Nat Immunol 2, 870-875,
36. Spence, J. et al. (1995) A ubiquitin mutant with specific defects in DNA repair and multiubiquitination. Mol Cell Biol 15, 1265-1273,
37. Morris, J.R. and Solomon, E. (2004) BRCA1 : BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum Mol Genet 13, 807-817,
38. Kanayama, A. et al. (2004) TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 15, 535-548,
39. Deng, L. et al. (2000) Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351-361,
40. Wang, C. et al. (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346-351,
41. Alam, S.L. et al. (2004) Ubiquitin interactions of NZF zinc fingers. Embo J 23, 1411-1421,
42. Hook, S.S. et al. (2002) Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes. Proc Natl Acad Sci U S A 99, 13425-13430,
43. Di Fiore, P.P., Polo, S. and Hofmann, K. (2003) When ubiquitin meets ubiquitin receptors: a signalling connection. Nat Rev Mol Cell Biol 4, 491-497,
44. Buchberger, A. (2002) From UBA to UBX: new words in the ubiquitin vocabulary. Trends Cell Biol 12, 216-221,
45. Yewdell, J.W., Schubert, U. and Bennink, J.R. (2001) At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J Cell Sci 114, 845-851,
46. Bonizzi, G. and Karin, M. (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25, 280-288,
47. Beinke, S. and Ley, S.C. (2004) Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 382, 393-409,
48. Senftleben, U. et al. (2001) Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293, 1495-1499,
49. McGettrick, A.F. and O'Neill, L.A. (2004) The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction. Mol Immunol 41, 577-582,
50. Janssens, S. and Beyaert, R. (2003) Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell 11, 293-302,
51. Takaesu, G. et al. (2003) TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. J Mol Biol 326, 105-115,
52. Hayden, M.S. and Ghosh, S. (2004) Signaling to NF-kappaB. Genes Dev 18, 2195-2224,
53. Habelhah, H. et al. (2004) Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. Embo J 23, 322-332,
54. Shi, C.S. and Kehrl, J.H. (2003) Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2). J Biol Chem 278, 15429-15434,
55. Wertz, I.E. et al. (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430, 694-699,
56. Tang, E.D. et al. (2003) A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha. J Biol Chem 278, 37297-37305,
57. Zhou, H. et al. (2004) Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 427, 167-171,
58. Sun, L. et al. (2004) The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 14, 289-301,
59. Duan, L. et al. (2004) The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. Immunity 21, 7-17,
60. Mueller, D.L. (2004) E3 ubiquitin ligases as T cell anergy factors. Nat Immunol 5, 883-890,
61. Lee, J.C. and Peter, M.E. (2003) Regulation of apoptosis by ubiquitination. Immunol. Rev 193, 39-47,
62. Bignell, G.R. et al. (2000) Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 25, 160-165,
63. Krikos, A., Laherty, C.D. and Dixit, V.M. (1992) Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Biol Chem 267, 17971-17976,
64. Laherty, C.D., Perkins, N.D. and Dixit, V.M. (1993) Human T cell leukemia virus type I Tax and phorbol 12-myristate 13-acetate induce expression of the A20 zinc finger protein by distinct mechanisms involving nuclear factor kappa B. J Biol Chem 268, 5032-5039,
65. Opipari, A.W., Jr., Boguski, M.S. and Dixit, V.M. (1990) The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 265, 14705-14708,
66. Lee, E.G. et al. (2000) Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289, 2350-2354,
67. Boone, D.L. et al. (2004) The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5, 1052-1060,
68. Song, H.Y., Rothe, M. and Goeddel, D.V. (1996) The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci U S A 93, 6721-6725,
69. Heyninck, K. et al. (1999) The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell Biol 145, 1471-1482,
70. Zetoune, F.S. et al. (2001) A20 inhibits NF-kappa B activation downstream of multiple Map3 kinases and interacts with the I kappa B signalosome. Cytokine 15, 282-298,
71. Zhang, S.Q. et al. (2000) Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity 12, 301-311,
72. Evans, P.C. et al. (2003) A novel type of deubiquitinating enzyme. J Biol Chem 278, 23180-23186,
73. Evans, P.C. et al. (2004) Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J 378, 727-734,
74. Park, S.M., Yoon, J.B. and Lee, T.H. (2004) Receptor interacting protein is ubiquitinated by cellular inhibitor of apoptosis proteins (c-IAP1 and c-IAP2) in vitro. FEBS Lett 566, 151-156,
75. Li, X., Yang, Y. and Ashwell, J.D. (2002) TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416, 345-347,
76. Brown, K.D., Hostager, B.S. and Bishop, G.A. (2002) Regulation of TRAF2 signaling by self-induced degradation. J Biol Chem 277, 19433-19438,
77. Habelhah, H. et al. (2002) Stress-induced decrease in TRAF2 stability is mediated by Siah2. Embo J 21, 5756-5765,
78. Noubir, S., Hmama, Z. and Reiner, N.E. (2004) Dual receptors and distinct pathways mediate interleukin-1 receptor-associated kinase degradation in response to lipopolysaccharide. Involvement of CD14/TLR4, CR3, and phosphatidylinositol 3-kinase. J Biol Chem 279, 25189-25195,
79. Nachmias, B., Ashhab, Y. and Ben-Yehuda, D. (2004) The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 14, 231-243,
80. Chuang, T.H. and Ulevitch, R.J. (2004) Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol 5, 495-502,
81. Ryo, A. et al. (2003) Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 12, 1413-1426,
82. Saccani, S. et al. (2004) Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J Exp Med 200, 107-113,
83. Janssen-Heininger, Y.M., Poynter, M.E. and Baeuerle, P.A. (2000) Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic Biol Med 28, 1317-1327,
84. Bowie, A. and O'Neill, L.A. (2000) Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 59, 13-23,
85. Imbert, V. et al. (1996) Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell 86, 787-798,
86. Lahdenpohja, N., Savinainen, K. and Hurme, M. (1998) Pre-exposure to oxidative stress decreases the nuclear factor-kappa B-dependent transcription in T lymphocytes. J Immunol 160, 1354-1358,
87. Zahler, S., Kupatt, C. and Becker, B.F. (2000) Endothelial preconditioning by transient oxidative stress reduces inflammatory responses of cultured endothelial cells to TNF-alpha. Faseb J 14, 555-564,
88. Luo, H. et al. (2001) A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 72, 196-202,
89. Berti, R. et al. (2003) Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat. Neurotox Res 5, 505-514,
90. Campbell, B. et al. (1999) Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 31, 467-476,
91. Pye, J. et al. (2003) Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 284, H919-926,
92. Sun, K. et al. (2004) Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 101, 8120-8125,
93. Meiners, S. et al. (2002) Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 105, 483-489,
94. Zhang, L. et al. (2001) Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 32, 2926-2931,
95. Palombella, V.J. et al. (1998) Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 95, 15671-15676,
96. Vanderlugt, C.L. et al. (2000) Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 14, 205-211,
97. Adams, J. (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417-421,
98. Adams, J. and Kauffman, M. (2004) Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 22, 304-311,
99. Park, D.J. and Lenz, H.J. (2004) The role of proteasome inhibitors in solid tumors. Ann Med 36, 296-303,
100. Lawrence, T. et al. (2001) Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 7, 1291-1297,
101. Jensen, D.E. and Rauscher, F.J., 3rd (1999) BAP1, a candidate tumor suppressor protein that interacts with BRCA1. Ann N Y Acad Sci 886, 191-194,